Cognitive impairment in bipolar disorder
Bipolar disorder is often defined by cycles of depression and mania, but many patients also struggle with lasting cognitive impairment. These difficulties can affect memory, attention, and executive functioning. Unfortunately, traditional mood stabilizers and antidepressants often fail to improve cognition and may even worsen it. This ongoing challenge has led researchers to explore new avenues, including NMDA receptor-modulating treatments in bipolar disorder.
The glutamate connection
Recent studies have pointed to the glutamatergic system, specifically the N-methyl-D-aspartate receptor (NMDAR), as a key player in cognitive health. Abnormalities in this system may contribute to the persistent attention, memory, and problem-solving difficulties seen in bipolar disorder. By modulating NMDA receptor activity, researchers hope to restore balance in brain signaling and strengthen cognitive function.
Memantine as an add-on therapy
One of the most studied NMDA receptor modulators is memantine, commonly used for Alzheimer’s disease. Early research suggests it may also support cognitive recovery in bipolar disorder. Memantine has been linked to improvements in memory after traumatic brain injury, better cognitive functioning in treatment-resistant bipolar patients, and enhanced mental clarity before electroconvulsive therapy (ECT). These findings suggest that adding memantine to standard treatment plans could be a safe way to boost brain performance in affected individuals.
Ketamine and cognition
Ketamine, widely known for its rapid antidepressant effects, is another NMDA receptor modulator drawing attention. Clinical studies show that ketamine infusions may improve processing speed and verbal learning in patients with bipolar disorder. This effect goes beyond mood stabilization and hints at ketamine’s broader potential as a cognitive enhancer. Still, more data are needed to understand whether these benefits are sustained and safe for long-term use.
Current challenges and next steps
While results are promising, NMDA receptor-modulating treatments in bipolar disorder are still in their early stages. Most studies have been small or short-term, making it difficult to draw firm conclusions. Longer and multicenter trials are needed to confirm their effectiveness and monitor potential side effects. Researchers are also investigating new NMDA receptor antagonists that may offer even more precise ways to target cognitive deficits.
Why this research matters
Cognitive impairment in bipolar disorder significantly impacts quality of life, even when mood symptoms are under control. Patients often report difficulty returning to work, managing relationships, or keeping up with daily tasks. By focusing on the brain mechanisms behind these challenges, NMDA receptor-modulating treatments open the door to more comprehensive care. Instead of only stabilizing mood, future treatments may also restore cognitive resilience, helping patients fully engage in life.
References
- Badrfam R, Zandifar A. NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review. Gen Hosp Psychiatry. 2025; https://www.sciencedirect.com/science/article/abs/pii/S0163834325001690?via%3Dihub
- McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015;(9):CD011611. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011611.pub2/full